Related Experiment Videos

Inhibitors of the complement system currently in development for cardiovascular disease

M K Pugsley1, M Abramova, T Cole

  • 1Department of Pharmacology, XOMA (US) LLC, Berkeley, CA 94710, USA. pugsley@xoma.com

Cardiovascular Toxicology
|April 2, 2003
PubMed

Insights

The complement system, crucial for immunity, can cause organ damage if improperly activated. This review explores complement pathways, regulation, cardiovascular roles, and therapeutic inhibitors for immune system control.

Area of Science:

  • Immunology
  • Biochemistry
  • Cardiovascular Medicine

Background:

  • The complement system is vital for host defense against pathogens.
  • Dysregulated complement activation can lead to severe organ damage.
  • Understanding complement control is key to managing inflammatory responses.

Purpose of the Study:

  • To review complement system activation pathways and regulatory mechanisms.
  • To examine the role of complement in cardiovascular diseases, including ischemia-reperfusion injury and cardiopulmonary bypass.
  • To provide an overview of current and developing complement inhibitors as therapeutic agents.

Main Methods:

  • Literature review of complement system pathways and regulation.
  • Analysis of complement's involvement in cardiovascular pathologies.
  • Survey of existing and emerging complement-targeting therapies.

Main Results:

  • Detailed explanation of complement activation cascades (classical, lectin, alternative).
  • Elucidation of intrinsic and extrinsic control mechanisms for complement.
  • Evidence linking complement activation to myocardial ischemia-reperfusion injury and cardiopulmonary bypass complications.

Conclusions:

  • Controlled complement activation is essential for immunity, but dysregulation causes disease.
  • Targeting complement pathways offers promising therapeutic strategies for cardiovascular and inflammatory conditions.
  • A range of complement inhibitors are progressing through discovery and clinical development.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...